Serious adverse events or complications of treatment
1 finding from 1 review
Serious adverse events or complications of treatment
1 finding from 1 review
Serious adverse events or complications of treatments
It is very uncertain whether percutaneous nephrolithotripsy changes serious adverse events or complications of treatments compared with tubeless percutaneous nephrolithotripsy (very low certainty).
1 finding from 1 review
Adverse events including suicide and suicide ideation · Informal caregivers of adults with diagnosed illnesses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events including suicide and suicide ideation · Informal caregivers of adults with diagnosed illnesses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infants with Probably Related Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers
It is very uncertain whether an extended NVP regimen administered to infants for 14 weeks changes infants with Probably Related Severe Adverse Events11 compared with sdNVP plus ZDV (1week) (very low certainty).
1 finding from 1 review
Adverse effects: suicidal thoughts (events) · people in the prodromal stage of psychosis
It is very uncertain whether group A: amino acids changes adverse effects: suicidal thoughts Short‐term (events) compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events ‐ Haemodilution versus control. · patients with liver resection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · participants with tophi in gout
Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events None of the included studies evaluated adverse events · young people (aged 10 to 18 years old) with harmful sexual behaviour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ total participants with adverse events · patients (mainly young male adults) with fractures of the middle third of the clavicle
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ in total population randomised · critically ill patients
Early physical therapy showed no clear difference in serious adverse events ‐ in total population randomised compared with control (moderate certainty).
1 finding from 1 review
Adverse events (wound dehiscence; lip scar hypertrophy) · Infants up to 6 months (from term) born with cleft lip, cleft palate or cleft lip and palate (Pierre Robin sequence or other syndromes…
1 finding from 1 review
Adverse events: one wound dehiscence and one hypertrophy of the lip scar, both in spoon-fed infants (Darzi 1996).
1 study · 40 participants
GRADE not reported
Rate of adverse events excluding falls (per person year) · people with Parkinson's disease
Summary of findings for cholinesterase inhibitors may leads to higher rate of adverse events excluding falls (per person year) compared with placebo (low certainty).
1 finding from 1 review
Adverse events related to the use of physical restraints · older people in general hospital settings
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found